After being fired, I became the light of medicine

Chapter 40: ITG Genotyping Phase III Begins (Click here to read, very important!)

(Front row reminder: Today is the most critical day. Whether you can be recommended depends on today! It is not easy to create new themes. Please help!)

AkaRx's sudden price reduction caused quite a stir, but Zhang Yang simply learned about it and then, just as he had planned, he fully devoted himself to the research and development of "ITG human myelopoietin".

Three days later, he walked into the clinical trial center with a Phase III clinical trial plan for "ITG Human Myelopoietin".

He was received by Feng Gang, deputy director of the center.

"Zhang Yang, long time no see. I missed you so much."

After the previous clinical trials of "Qingshan Avatrombopag Tablets", Feng Gang and Zhang Yang's relationship became better and better.

"Director Feng, your words may cause misunderstanding!"

"Ha ha!"

Feng Gang smiled and patted Zhang Yang on the shoulder, his eyes then fell on the document in Zhang Yang's hand.

"What's up? Are you here to submit your Phase II clinical trial plan for 'ITG epoxin' again today?"

Zhang Yang shook his head:

"You are such a forgetful person. We have already passed the Phase II clinical trial."

"This is our latest Phase III clinical design for 'ITG Genotyping'. Several parts have been modified, so I resubmitted it on purpose."

"Oh~"

Feng Gang deliberately lengthened his voice, with a hint of a smile on his lips.

Of course he knew that Qingshan Pharmaceutical's "ITG Human Myelopoietin" had passed the Phase II trial, and it was revised five times in a row before it finally passed!

The reason I ask this is because the previous "Qingshan Avatrombopag" tablets were really weird. The drug ingredients, dosage, and all parameters have not been modified once!

Now this "ITG human myelopoietin" is finally normal. After modifying the drug composition five times in a row, it finally completed the second phase of the trial.

Yeah!

This is the normal process of innovative drug research and development!
"Okay, let me take a look and see what you have modified."

Zhang Yang handed over the Phase III clinical design plan without showing any expression, but the next second, Feng Gang suddenly stood up with an expression of disbelief on his face!
"This... Zhang Yang, what are you doing?!"

“Not only has the drug’s positioning changed, but the ultimate therapeutic effect has also changed?!”

"If I remember correctly, in your previous Phase II clinical trial design, 'ITG human myelopoietin' was designed as an adjuvant therapy drug. Now... you're telling me you want to change it to a first-line drug?!"

"and!"

"Look at what you wrote about the treatment effect!"

“We want to achieve a cure rate of more than 95% for aplastic anemia!”

"Heal, not treat!"

Zhang Yang didn't say anything, just nodded and smiled slightly.

"You're absolutely crazy!"

Feng Gang was furious, but the next second he suddenly remembered the recent rumors about the fierce competition between Qingshan Pharmaceutical and AkaRx. He took a deep breath and adjusted his mood.

“Zhang Yang, I know you’re under a lot of pressure, but please don’t be so stressed out.”

"Have you ever thought about how long it will take for this 'ITG human myelopoietin' to achieve the designed therapeutic effect and pass Phase III clinical trials?"

Zhang Yang exhaled lightly; he could hear the concern in Feng Gang's words.

but……

What Feng Gang didn’t know was that “ITG human myelopoietin” was not an auxiliary treatment drug from the beginning. From the very beginning, it was a special medicine that could truly and completely cure “aplastic anemia”!
The previous Phase II clinical trial was revised five times. This was just a trick to deceive others!

Now the time is ripe, and it is time for "ITG Human Myelopoietin" to show its due effect!

"Director Feng, I know you are concerned about me, but I am very sure, so just report it for approval." Looking at Zhang Yang's confident look, Director Feng was completely shocked.

After a moment, he looked at the latest phase III clinical plan of "ITG eukogenogen" on the table, and the previous clinical plan of "Qingshan Avatrombopag Tablets" came to his mind, and he suddenly got an idea.

Oh my god.

I originally thought this was a normal medicine, but I didn’t expect it to be even more evil than “Qingshan Afa”!
……

The changes in the design of the Phase III clinical trial of "ITG Human Myelogenin" were quickly approved.

After approval, it also means that "ITG Human Myelopoietin" can officially undergo phase III clinical trials.

but.

When the approved Phase III clinical trial plan was transferred to the Department of Hematology, Director Hu was the first to notice the abnormality of "ITG human myelopoietin"!

As the director of the Department of Hematology, he naturally needs to have a general understanding of the new drugs undergoing clinical trials in the department.

"What does Feng Gang do? How could he allow Qingshan Pharmaceutical to submit such an obviously faulty design for approval?"

"To achieve a 95% cure rate for aplastic anemia?"

"And the indications include mild aplastic anemia, common aplastic anemia and very severe aplastic anemia, which means that all types of aplastic anemia can be cured regardless of their type!"

"Is this a normal design? Which pharmaceutical company would dare to design like this?"

"Does Feng Gang understand how difficult it is to cure aplastic anemia?"

Director Hu was very angry.

You should know that in the clinical trial plan, the most important assessment is "effective treatment effect"!
Therefore,
In order to improve the effective therapeutic effects of drugs, major pharmaceutical companies often impose restrictions on indications when designing clinical plans, so that new drugs can more accurately treat patients with only a certain disease.

For example, a targeted drug used to treat lung cancer will not only require that only patients with the corresponding target be enrolled in the clinical trial, but will also impose strict restrictions on details such as whether the patient has a history of chemotherapy, radiotherapy, other targeted drug treatment experience, and other medical history.

In short, the goal is to eliminate interference and achieve the ideal treatment rate, thereby speeding up the time to market!

And now,
What is Feng Gang doing!
It's fine for mild cases, but it's even more severe than severe aplastic anemia, and the whole system needs to be cured!

is it possible? !
Thinking of this, he hurriedly took out his phone to call Feng Gang, but as soon as he took out the phone, he suddenly thought of Zhang Yang and thought of another possibility.

Is it possible that this is the plan modified by Zhang Yang?
hiss!
Director Hu suddenly became excited, his heart was pounding, and his original anger was replaced by excitement.

He didn't have time to contact Feng Gang and hurriedly found Zhang Yang's phone number.

As soon as the call was connected, he asked urgently:
"Zhang Yang, I just saw your latest Phase III clinical trial plan for 'ITG Human Myelopoietin', and the treatment effect has been changed to complete cure!"

"Did you change it yourself? Are you sure?"

Ever since Director Hu and other doctors in the department signed the agreement, Zhang Yang has always remembered Director Hu's kindness.

After a brief silence, he said:

"Yes, I changed it. I'm sure of it!"

"Good, good, good!"

Director Hu said this three times in a row, then took a deep breath:

"I believe you. I will immediately arrange for all the doctors in the department to fully support your Phase III clinical trial!"

Half an hour later, the Phase III clinical recruitment information of "ITG Human Myelopoietin" appeared in a prominent position in the inpatient department!

After a while, the whole department suddenly exploded!

　PS: Thanks to book friend 202312223201520650 for the reward of 100 coins.

　　Thanks to CCD7057 for 1 monthly ticket, and thanks to Great Evil is Great Good for 2 monthly tickets

　　
　
(End of this chapter)